These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 9452278

  • 1. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
    Wolanski KD, Whitaker D, Shilkin KB, Henderson DW.
    Cancer; 1998 Feb 01; 82(3):583-90. PubMed ID: 9452278
    [Abstract] [Full Text] [Related]

  • 2. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
    Bethwaite PB, Delahunt B, Holloway LJ, Thornton A.
    Pathology; 1995 Jan 01; 27(1):1-4. PubMed ID: 7603742
    [Abstract] [Full Text] [Related]

  • 3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K.
    Pneumonol Alergol Pol; 2007 Jan 01; 75(1):57-69. PubMed ID: 17541913
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
    King J, Thatcher N, Pickering C, Hasleton P.
    Histopathology; 2006 Dec 01; 49(6):561-8. PubMed ID: 17163840
    [Abstract] [Full Text] [Related]

  • 5. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
    Metze K, Trevisan MA.
    Cancer; 1999 Jan 01; 85(1):250. PubMed ID: 9922003
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of AgNOR count in distinguishing benign from malignant mesothelial cells in pleural fluids.
    Colecchia M, Leopardi O.
    Pathol Res Pract; 1992 Jun 01; 188(4-5):541-4. PubMed ID: 1409085
    [Abstract] [Full Text] [Related]

  • 7. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM, Butcher DN, Corrin B, Nicholson AG.
    J Pathol; 1999 Oct 01; 189(2):251-7. PubMed ID: 10547583
    [Abstract] [Full Text] [Related]

  • 8. [Utility of morphometry and nucleolar organizer regions count in the differentiation of reactive and malignant mesothelial cells in pleural effusions].
    Colecchia M, Agnelli T, Caronni E, Leopardi O.
    Pathologica; 1991 Oct 01; 83(1083):89-97. PubMed ID: 1866205
    [Abstract] [Full Text] [Related]

  • 9. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F, Lin GY, Weidner N, Michael CW.
    Cancer Cytopathol; 2010 Apr 25; 118(2):90-6. PubMed ID: 20209622
    [Abstract] [Full Text] [Related]

  • 10. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN, Griffiths M, Papadaki L, Happerfield L, Bobrow L.
    J Pathol; 1991 Apr 25; 163(4):299-305. PubMed ID: 2033489
    [Abstract] [Full Text] [Related]

  • 11. Manual and automated AgNOR count in differentiating reactive mesothelial from metastatic malignant cells in serous effusions.
    Mohanty SK, Dey P, Rana P.
    Anal Quant Cytol Histol; 2003 Oct 25; 25(5):273-6. PubMed ID: 14603724
    [Abstract] [Full Text] [Related]

  • 12. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
    Epstein JI, Budin RE.
    Hum Pathol; 1986 May 25; 17(5):514-9. PubMed ID: 2422109
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT, Gentile P, Tarectecan A, Fuchs A.
    Arch Pathol Lab Med; 1996 Oct 25; 120(10):959-66. PubMed ID: 12046609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
    Saad RS, Cho P, Liu YL, Silverman JF.
    Diagn Cytopathol; 2005 Mar 25; 32(3):156-9. PubMed ID: 15690334
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic relevance of silver stained nucleolar organizer region (AgNORs) in benign and malignant breast lesions.
    Agarwal PK, Mehrotra A, Chandra T.
    Indian J Exp Biol; 1995 Oct 25; 33(10):715-20. PubMed ID: 8575800
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M, Florence RR, Pantanowitz L, Visintainer PF, Cibas ES, Otis CN.
    Diagn Cytopathol; 2013 Feb 25; 41(2):131-40. PubMed ID: 23002041
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.